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Abstract 17 
 18 
There is little peer-reviewed research assessing therapeutic effectiveness in canine eye disease.   19 
Current treatments used in first opinion and ophthalmology referral practices are also somewhat 20 
poorly documented.  The aim of this study was to investigate the current management of canine 21 
keratoconjunctivitis sicca (KCS) and acute primary angle-closure glaucoma (PACG) by veterinary 22 
surgeons.  Questionnaires using clinical vignettes were administered to a cross section of general 23 
practitioners (‘GPs’) and veterinarians engaged in or training for postgraduate ophthalmology 24 
practice (’PGs’).  Similar treatment recommendations for KCS (topical cyclosporine, lubricant, 25 
antibiotic) were given by both groups of veterinarians with the single exception of increased topical 26 
antibiotic use by GPs.  Treatment of acute glaucoma diverged between groups: PGs were much more 27 
likely to recommend topical prostaglandin analogues (PGAs) and a wider array of both topical and 28 
systemic treatments were recommended by both groups.  Systemic ocular hypotensive agents were 29 
suggested infrequently.  Our results suggest that treatments may vary substantially in ocular 30 
conditions, particularly in conditions for which neither guidelines nor high quality evidence exists.   31 
This study highlights the need for novel strategies to address evidence gaps in veterinary medicine, 32 
as well as for better evaluation and dissemination of current treatment experience.   33 
 34 
Introduction 35 
 36 
Keratoconjunctivitis sicca (KCS) and acute angle-closure glaucoma (PACG) can cause significant 37 
disability in dogs (Chester and Clark, 1987).  Incidence and prevalence data for each is not well 38 
established but risks appear to be higher in some breeds and with increasing age (Gelatt and 39 
MacKay, 2004a; Sanchez and others, 2007).  Veterinarians routinely encounter these and other 40 
clinical conditions for which there is limited evidence available to guide clinical decision making.  41 
  
Currently there is only one veterinary pharmaceutical approved for the treatment of KCS and none 42 
for the treatment of glaucoma;  it is unknown how this may affect treatment choice but could 43 
potentially result in diverse management strategies.   44 
 45 
Numerous clinical guidelines have been developed for the treatment of human disease, in part to 46 
address unwanted treatment variation and to improve quality of care (Timmermans and Mauck, 47 
2005).  In medicine, greater treatment variation is seen for interventions which have uncertain or 48 
marginal benefit and for conditions which lack clinical guidelines (Skinner, 2011).  Veterinary 49 
guidelines rely more heavily on consensus due to a small evidentiary base but areas with greater 50 
treatment uncertainty are argued to be most needful of guidance (Polzin and Cowgill, 2013).  While 51 
guidelines and consensus statements now exist for a number of companion animal conditions (e.g. 52 
Atkins and others, 2009; Podell and others, 2016; Olivry and others, 2010), we are unaware of any 53 
clinical guidelines for canine ophthalmic disease.    54 
 55 
Clinical vignette-based questionnaires are a useful way of assessing treatment patterns and variation 56 
in clinical practice; they have been used to assess adherence to guidelines and to assess factors in 57 
clinical decision-making in medicine (Peabody and others, 2004; Veloski and others, 2005).  58 
Additionally, vignettes have been combined with Delphi methodology to achieve expert consensus in 59 
optimizing treatment, as well as in establishing evidence gaps (Rose and Kagan, 1998).  Use of open, 60 
rather than closed, questions in vignettes has been reported to better describe clinicians’ actual 61 
practice patterns (Pham and others, 2009) and provide insight into what is accepted current 62 
practice.  63 
 64 
The aim of this study was to survey veterinarians about the current management of KCS and acute 65 
glaucoma.  Additionally, we aimed to explore the variation in treatment amongst all veterinarians 66 
and between general practitioners and veterinarians with postgraduate training in ophthalmology. 67 
 68 
Materials and methods 69 
 70 
Sampling and data collection 71 
The target population was all members of the veterinary profession in the UK.  The sampling frames 72 
were a convenience sample of veterinarians on a mailing list held by the Centre for Evidence-based 73 
Veterinary Medicine (CEVM) (identified from another survey initially approaching respondents using 74 
a list of RCVS members who were willing to be contacted, Nielsen and others, 2014), and attendees 75 
at the British Association of Veterinary Ophthalmologists (BrAVO) Winter conference (2011).  76 
 77 
A questionnaire (Appendix 1) was constructed consisting of 22 open and closed-end questions across 78 
five sections as part of a student research project (Corinne Wigfall).  These sections covered the 79 
diagnostic tools used for ophthalmological cases, the sources of information accessed by vets and 80 
factors considered in clinical decision-making for ocular conditions, as well as questions relating to 81 
respondent demographics (age, gender, year of graduation, ophthalmology postgraduate 82 
certification or training).  The additional two sections presented two clinical vignettes—the first 83 
based on a West Highland White Terrier with KCS and the second a Cocker Spaniel presenting with 84 
acute PACG.  After each vignette, veterinarians were asked what treatments, additional 85 
investigations, long term management and recheck advice they would give for each case.  The design 86 
  
of the vignettes was based on “textbook” cases to minimize diagnostic confusion while the 87 
associated questions were derived from a similar survey undertaken by Davies (2015).  The 88 
questionnaire was pre-tested by 20 people, and piloted by eight veterinarians and three non-89 
clinicians.  90 
 91 
An online questionnaire was constructed and administered through cloud-based software 92 
(SurveyMonkey Inc., California, USA) to the CEVM mailing list.  Online respondents were  93 
encouraged  to  fill out  the  questionnaire  by  being entered  into  a  prize  draw  for  a  £50  gift; 94 
respondents were anonymized for analysis.  The online survey was initiated October 26, 2011 and 95 
closed November 18, 2011.  A first reminder was sent 2 weeks after the initial email followed by a 96 
final reminder two days before survey close.  Paper questionnaires identical in sequence and content 97 
to the online questionnaire were distributed to the attendees during one day of the British 98 
Association of Veterinary Ophthalmologists Winter conference and were collected back by three of 99 
the authors at the end of the day (November 5, 2011). 100 
 101 
Ethical approval for the study was received from the ethics committee at the School of Veterinary 102 
Medicine and Science at The University of Nottingham.  103 
 104 
Data management and analysis  105 
Returned online responses were downloaded to Microsoft Excel V.14.0.6 (2010 Microsoft 106 
Corporation) whilst paper questionnaire responses were manually entered into the same 107 
spreadsheet.  Data relating to proposed treatments and diagnostic investigations were extracted 108 
from open ended responses by one coder (Constance White) and categorically classified into generic 109 
drug name and/or category, surgical or procedural interventions, diagnostic test, and other patient 110 
assessments.  Data relating to long term recommendations were extracted by one coder (Constance 111 
White) and classified into categories relating to prognosis, salvage treatment options, chronicity, and 112 
owner communication/compliance.  Suggested reevaluation times were converted from text to 113 
numerals and where ranges were given, mean time calculated.   114 
 115 
Statistical analysis was performed with a commercially available statistical package (Stata IC13).  116 
Continuous data (age, years since graduation, recheck intervals) were assessed for normality by the 117 
Shapiro-Wilk normality test and were subsequently analyzed using Mann-Whitney U tests.  Chi-118 
square tests were used to compare categorical data between groups except when expected cell 119 
counts were ≤ 5, where the more conservative Fisher’s exact test was used. Not all respondents 120 
answered all questions; proportions are calculated using the total numbers of respondents 121 
completing each question unless otherwise indicated.  Statistical significance was set at the 0.05 122 
level; when multiple comparisons were undertaken, p values were adjusted for significance at this 123 
level with the Dunn-Bonferroni method (Pagano and others, 2009).  In brief, for a p value to reach 124 
significance with correction for multiple comparisons, value must be <0.05/k where k is the number 125 
of comparisons.  Significant p values are reported in text when not included in tables. 126 
 127 
 128 
Results 129 
 130 
  
Response rate 131 
Of 1421 successful email invitations, 490 (34.5%) online questionnaires were returned.  Of those, 132 
392 were from veterinarians engaged in small animal practice.  Sixty one paper questionnaires were 133 
returned by British Veterinary Ophthalmologist Association (BrAVO) conference attendees (total 134 
number of conference attendees unknown).  Of the total number of eligible responses (453), 70 135 
were engaged in or training for postgraduate ophthalmology practice; from here on known as ‘PGs’) 136 
while 383 were engaged in general practice (from here on known as ’GPs’).  Not all 453 respondents 137 
answered all questions within the questionnaire (Table 1).  138 
 139 
Table 1  Demographic and vignette question response rate.  KCS = Keratoconjunctivitis sicca 140 
 141 
 Overall n Overall % GP n GP % PG n PG % 
Survey 453 100 383 100  70 100 
Age 330 72.8 260 67.9 70 100 
Gender 332 73.3 262 68.4 70 100 
Graduation year 331 73.1 261 68.1 70 100 
KCS treatment 399 88.1 329 85.9 70 100 
Further investigation KCS 395 87.2 195 50.9 53 75.7 
KCS diagnostics 252 55.6 197 51.4 55 78.6 
KCS recheck interval 396 87.4 326 85.1 70 100 
KCS long term management 334 73.7 266 69.5 68 97.1 
Glaucoma treatment 330 72.8 260 67.9 70 100 
Glaucoma further investigation 323 71.3 254 66.3 69 98.6 
Glaucoma diagnostics 260 57.4 191 50.0 69 98.6 
Glaucoma recheck interval 259 57.2 206 53.8 53 75.7 
Glaucoma long term management 262 57.8 194 50.6 68 97.1 
 142 
 143 
Respondent characteristics 144 
Sixty three percent of all respondents were female, with a somewhat higher proportion of males in 145 
the PG group, a difference which did not reach statistical significance.  Overall median age of 146 
respondents was 37 years, with PGs significantly older than the GP group.  Median year of 147 
qualification was significantly earlier for PGs than for GPs.  Analysis stratified by gender did not 148 
eliminate age or year of qualification differences between PGs and GPs (Table 2).  When participants 149 
were de-anonymized by email address subsequent to analysis, credentials and practice type could be 150 
ascertained for 41 of the 70 PG respondents.  Of those, eight were RCVS Specialists in 151 
ophthalmology, 28 were designated ophthalmology certificate holders (26/28 CertVOphthal), four 152 
were ophthalmology certificate candidates, and one was a non-identified certificate candidate.  153 
Overall, 88% (36/41) of those successfully de-anonymized were in referral practice at the time of the 154 
survey. 155 
 156 
Table 2 Participant responses to demographic questions, comparison between practitioner groups 157 
 Overall n Overall GP n GP PG n PG p value 
Gender        
Male 123 37.0% 91 34.7% 32 45.7% 0.091 
Female 209 63.0% 171 65.3% 38 54.3%  
No answer given  121  121  0   
  
Age        
Median age (all) 330 37.0 260 35.5 years 70 42.0 years *0.0002 
Median age (male) 123 41.0 91 40.0 years 32 45.5 years *0.0212 
Median age (female) 206 35.0 168 33.0 years 38 38.5 years *0.0036 
No answer given  123  124  0   
Year of qualification        
Median year qualified (all)  331 1998 261 2001 70 1995 *0.0001 
Median year qualified (male)  123 1995 91 1996 32 1989 *0.0093 
Median year qualified (female) 207 2001 169 2002 38 1998 *0.0055 
No answer given 122  122  0   
Categorical data chi square test.  Continuous data Mann-Whitney test  158 
*Significant with Bonferroni corrected p <0.05 159 
 160 
 161 
Keratoconjunctivitis sicca 162 
Initial KCS treatment recommendations were offered by 399 respondents.  Six different topical 163 
treatments were nominated (Table 3).  The majority of both groups recommended cyclosporine 164 
(CSA) and an ocular lubricant.  However, a significantly larger portion of GPs suggested using topical 165 
antibiotics.  166 
 167 
Most respondents suggested a combination of topical therapies; a wider range of combinations 168 
were offered by GPs (GPs 12 combinations, PGs 8 combinations).  A majority (98%) of respondents 169 
suggested one of eight different combinations of the four most common topicals (Figure 1).  The top 170 
four combinations were recommended by 85.1% of GPs and 90.0% of PGs.  PGs were significantly 171 
more likely to use topical CSA in combination with lubricant as sole treatment (chi square p=0.001) 172 
but no other significant differences were found.    Amongst both groups, there were few 173 
recommendations of systemic therapies:  34 veterinarians recommended a systemic nonsteroidal 174 
anti-inflammatory (NSAID), eight veterinarians recommended systemic antibiotics, and one 175 
recommended systemic steroids for initial treatment. 176 
 177 
Of 395 veterinarians who considered whether further investigation of KCS was warranted, a majority 178 
(63.8%) recommended further diagnostic tests (Figure 2).  The most common suggestion was 179 
fluorescein staining.   PGs were significantly more likely to recommend culture, tear film breakup 180 
testing, slit lamp evaluation, and Rose Bengal staining when compared to GPs (p<0.003 for each 181 
item, Fisher's exact test).  Small numbers of respondents (<12 per recommendation) suggested 182 
evaluation for drug history, atopic dermatitis, and neurogenic causes of dry eye.  Suggested recheck 183 
intervals differed significantly between GPs and PGs.  Median time suggested for first recheck was 7 184 
days (range 2-52, IQR 7-14 days) for GPs versus a median of 14 days (range 5-60, IQR 12-28 days) for 185 
PGs (Mann Whitney U p=0.0000). 186 
 187 
More than 40% of both groups discussed the need for long term therapy and regular assessment.  188 
Although the questionnaire did not solicit recommendations for refractory disease, multiple 189 
respondents offered suggestions in case of treatment failure:  twelve individuals recommended 190 
compounded cyclosporine ophthalmic suspension while six suggested tacrolimus.  Parotid duct 191 
transposition was considered by ten respondents in each group.   192 
 193 
  
 194 
Table 3 Topical treatment recommendations for KCS by participants. NSAID = Nonsteroidal anti-195 
inflammatory drug 196 
Treatments Overall n Overall % GP n GP % PG n PG % p value  
Cyclosporine 371 93.0 304 92.4 67 95.7 0.324 
Lubricant or tear 
replacement 
319 78.0 256 77.8 63 90.0 0.021 
Antibiotic 277 69.4 239 72.6 38 54.3 *0.002 
Steroid 58 14.5 44 13.4 14 20.0 0.153 
Tacrolimus 2 0.5 0 0.0 2 2.9 ǂ0.030 
Topical NSAID 1 0.25 0 0.0 1 1.4 ǂ0.175 
*Significant with Bonferroni corrected p <0.05, chi square test unless otherwise indicated 197 
ǂ Fisher’s exact test 198 
 199 
 200 
Acute Glaucoma 201 
A total of 330 veterinarians made treatment recommendations for PACG. Half of all GPs indicated a 202 
desire to refer the glaucoma patient acutely but many of those also suggested some initial 203 
treatments. Ten topical agents for PACG management were nominated (Table 4).  Of those, PGs 204 
were significantly more likely to recommend a prostaglandin analogue (PGA) and steroid.  GPs 205 
suggested the use of pilocarpine significantly more often than PGs.  Respondents who suggested 206 
pilocarpine were not significantly different in age (Mann Whitney U p=0.5989), years of qualification 207 
(Mann Whitney U p=0.8615), or gender from other veterinarians (chi square p=0.428).  There were 208 
small but significant differences in choice of CAI and PGA agents selected, with a greater fraction of 209 
PGs suggesting brinzolamide and travoprost. 210 
  211 
Nineteen combinations of the five most commonly suggested topicals were recommended by 212 
respondents (GPs 18 combinations, PGs 10 combinations).  The ten most common combinations 213 
were suggested by 72.6% of GPs and 95.7% of PGs (Figure 3).  The top four combinations were 214 
recommended by 55.3% of GPs and 77.2% of PGs.  More than half (52.9%) of PGs chose a PGA 215 
(typically latanoprost or travoprost) in combination with a carbonic anhydrase inhibitor (CAI; 216 
predominately dorzolamide), with or without additional timolol and/or topical steroid.   GPs 217 
nominated PGAs significantly less often and were more likely to suggest a CAI alone or in 218 
combination with topicals other than PGAs.  Fewer GPs suggested CAI in fixed combination with 219 
timolol (GPs 15 of 148 CAI suggestions, PGs 13 of 50 CAI suggestions, chi square p=0.001). 220 
 221 
Many systemic therapies were also recommended (Table 5).  Analgesic or anti-inflammatory drugs 222 
were suggested by a large proportion, with NSAIDs most frequently specified.  Twenty individuals 223 
used a combination of products.  Small numbers of respondents recommended systemic mannitol or 224 
CAI to reduce intraocular pressure (IOP).  A handful of respondents recommended antihypertensive 225 
or diuretic drugs.  No significant differences were found between GPs and PGs in their 226 
recommendations for systemic agents.    227 
 228 
Of the 260 respondents who answered questions about further investigations, the majority (79.0%) 229 
recommended further diagnostics but few GPs made specific diagnostic recommendations (Figure 230 
  
4).  PGs suggested gonioscopy, slit lamp evaluation, ocular ultrasound, and Schirmer tear testing at 231 
significantly greater rates than GPs (chi square p<0.001 for each test).  After adjustment for access to 232 
a gonioscopy lens, PGs were still significantly more likely to recommend gonioscopy (chi square 233 
p=0.000).  Specific assessment for uveitis (n=7), lens luxation (n=27), and vision (n=7) were 234 
recommended by a minority of each group.  A significantly higher proportion of PGs recommended 235 
evaluation of the contralateral eye (3.1% GPs, 27.5% PGs, chi square p=0.000).    236 
 237 
Suggested recheck intervals did not significantly differ between GPs and PGs.   Median time 238 
suggested for first recheck was 1.5 days (range 1-14, IQR 1-3 days) for GPs versus a median of 2 days 239 
(range 0.6-7, IQR 1-3.5 days) for PGs.  More than a third of PGs (n=25) recommended hospitalization 240 
until IOP normalized, a significantly greater proportion than GPs (n=12, chi square p<0.001).   241 
 242 
Of the 262 respondents who gave long term management recommendations, PGs and GPs were 243 
equally likely to discuss the need for ongoing treatment of glaucoma (11.9% GPs, 17.9% PGs), regular 244 
monitoring (30.4 % GPs, 36.2% PGs), and long term prognosis (13.4% GPs, 20.3% PGs).  More than 245 
half of PGs (56.5%) discussed evaluation, prognosis and/or prophylaxis of the contralateral eye, 246 
whilst significantly fewer GPs (23.7%) did so (chi square p=0.000).   247 
 248 
 249 
Table 4 Topical treatment recommendations for acute glaucoma by participants. NSAID = 250 
Nonsteroidal anti-inflammatory drug 251 
Treatments Overall n Overall % GP n GP % PG n PG % p value  
Carbonic anhydrase inhibitor 198 60.0 148 56.9 50 71.4 0.028 
Dorzolamide 151 45.8 123 47.3 28 40.0 0.276 
Brinzolamide 31 9.4 15 5.8 16 22.9 *0.000 
Either 11 3.3 7 2.7 4 5.7  
Unspecified 5 1.5 3 1.2 2 2.8  
Prostaglandin analogue 128 38.8 72 27.7 56 80.0 *0.000 
Latanoprost 81 24.5 53 20.4 28 40.0 *0.001 
Travoprost 33 10.0 14 5.4 19 27.1 *0.000 
Either 7 2.1 0 0 7 10.0  
Unspecified 7 2.1 5 1.9 2 2.9  
Timolol 41 12.4 27 10.4 14 20.0 0.030 
Steroid 30 9.1 16 6.2 14 20.0 *0.000 
Pilocarpine 30 9.1 30 11.5 0 0 *0.003 
Atropine 13 4.0 13 5.0 0 0 ǂ0.078 
NSAID (topical) 12 3.6 12 4.6 0 0 ǂ0.078 
Antibiotic 10 3.0 9 3.5 1 1.4 ǂ0.695 
Lubricant 6 1.8 5 1.9 1 1.4 ǂ1.000 
Iopidine 1 0.3 0 0 1 1.4 ǂ0.212 
*Significant with Bonferroni corrected p <0.05, chi square test unless otherwise indicated 252 
ǂ Fisher’s exact test 253 
 254 
 255 
  
Table 5 Systemic glaucoma therapies suggested by participants. NSAID = Nonsteroidal anti-256 
inflammatory drug; IOP = Intraocular pressure; IV = Intravenous; CAI = Carbonic Anhydrase Inhibitor; 257 
ACE = Angiotensin Converting Enzyme 258 
Treatments Overall n Overall % GP n GP % PG n PG % p value   
Pain/antiinflammatory          
NSAID 155 47.0 118 45.4 37 52.9 0.266  
Unspecified analgesia 25 7.6 24 9.2 1 1.4 ǂ0.038  
Opioid or tramadol 19 5.8 10 3.8 9 12.9 *0.004  
Glucocorticoid 4 1.2 3 1.2 1 1.4 ǂ1.000  
All pain/antiinflammatory 183 55.5 144 55.3 39 55.7 0.961  
IOP agents          
IV mannitol 34 10.3 26 10.0 8 11.4 0.727  
Oral CAI 17 5.2 16 6.2 1 1.4 ǂ0.137  
Hypotensives/diuretics         
Amlodipine 2 0.6 0 0.0 2 2.9 ǂ0.044  
ACE inhibitor 1 0.3 1 0.4 0 0.0 ǂ1.000  
Furosemide 4 1.2 4 1.5 0 0.0 ǂ0.582  
Referral 133 40.3 130 50.0 3 4.3  *0.000  
*significant with Bonferroni corrected p<0.05, chi square test unless otherwise indicated 259 
ǂ Fisher’s exact test 260 
 261 
 262 
Discussion 263 
 264 
Prior work has established that substantial treatment variation may occur in the management of 265 
canine diabetes and heart failure (Davies and others, 2015; Sinclair and others, 2014).   This study 266 
demonstrates similar variation, particularly in the treatment of PACG.  We speculate that this 267 
variation may be driven by knowledge gaps influenced by one or more of the following factors:  lack 268 
of evidence-based and/or consensus guidelines, access to information, or differences in caseload 269 
and/or practice setting.   270 
  271 
For KCS, fairly robust evidence (grade I, Roudebush and others, 2004) exists for topical CSA efficacy 272 
in prospective clinical trials and an approved veterinary ophthalmic preparation has been available 273 
for more than two decades (Kaswan and others, 1989; Morgan and Abrams, 1991; Olivero and 274 
others, 1991; Sansom and others, 1995).  Frequent nomination of CSA for KCS treatment likely 275 
reflects acceptance of efficacy and incorporation into standards of care.  The preference for CSA 276 
over tacrolimus may be driven by CSA’s availability as a licensed veterinary product as well as 277 
current evidence which suggests equal efficacy of CSA and tacrolimus for treatment-naïve KCS 278 
(Berdoulay and others, 2005, Hendrix and others, 2011).  Similarly, there was general agreement in 279 
favour of topical lubricant.  Prior to the introduction of CSA, lubricants were the mainstay of KCS 280 
medical therapy (Blogg, 1980) and, extrapolating from human dry eye, may be reasonably expected 281 
to provide some symptomatic relief and corneal protection (Alves and others, 2013). 282 
 283 
Apart from CSA, most topicals used in KCS have limited published evidence for efficacy and this may 284 
account for wider variation in their recommended use.  There is sparse data regarding the 285 
  
prevalence of secondary infection with conflicting recommendations for antibiotic use in KCS 286 
(Giuliano and Moore, 2007; Maggs and others, 2012; Martin, 2010; Petersen-Jones, 1997; Salisbury 287 
and others, 1995).  Topical steroids are suggested by some veterinary ophthalmologists to decrease 288 
conjunctival inflammation, discomfort and corneal scarring in KCS (Giuliano and Moore, 2007).  289 
Topical steroid recommendations appear to rely on clinician experience and possibly extrapolation 290 
from the human literature which has shown benefit in dry eye (Messmer, 2015). 291 
 292 
While broad general agreement was found for KCS management, treatment suggestions for PACG 293 
were more varied.  GPs nominated topical PGAs significantly less frequently than did PGs while use 294 
of CAIs was more similar between the two groups.  There is reasonable evidence (grade III, 295 
Roudebush and others, 2004) for both PGA and CAI efficacy for IOP reduction in beagles with open-296 
angle glaucoma, with PGAs offering superior duration and magnitude of IOP reduction (Gelatt and 297 
McKay, 2001a, 2001b, 2002, 2004b; Plummer and others, 2006).  However, no clinical trials assessing 298 
safety or efficacy of these agents alone or in combination have been reported for the more common 299 
syndrome of PACG (reviewed by Maślanka, 2015a, 2015b).  Topical PGAs are preferred over systemic 300 
agents in achieving IOP reduction by some authors (Alario and others, 2015; Maślanka, 2015b), a 301 
view that was paralleled by our results.  Clinical uncertainty in recognizing PGA contraindications 302 
(anterior lens luxation and uveitis) may account for the lower rate of GP recommendation.  303 
However, other factors may play a role in differential recommendations: pilocarpine has similar 304 
contraindications yet was recommended by a number of GPs.  It is striking that no PG recommended 305 
pilocarpine; veterinary ophthalmologists appear to discourage pilocarpine due to ocular irritation 306 
and perceived superiority of other ocular hypotensives (Alario and others, 2015). Choice of topical 307 
PGA and CAI also varied between GP and PG groups with the latter group nominating travoprost and 308 
brinzolamide significantly more frequently.  Reasons for product choice were not elicited in our 309 
questionnaire and we are unaware of any comparative efficacy trials between dorzolamide and 310 
brinzolamide, or between latanoprost and travoprost, in acute canine glaucoma; however, 311 
brinzolamide is suggested to result in less ocular irritation relative to dorzolamide (Alario and others, 312 
2015).  Likewise, more PGs recommended a topical steroid.  Although we did not elicit the clinical 313 
reasoning behind treatment suggestions, steroids may have been recommended due to the putative 314 
role of inflammation in both genesis and progression of PACG (Dees and others, 2014; Reilly and 315 
others, 2005); steroids may exacerbate ocular hypertension in cats and dogs but the response may 316 
vary by individual and with the concurrent use of PGA (Herring, Herring, and Ward, 2004; Gelatt and 317 
McKay, 1998; Gosling and others, 2016; Kahane and others, 2016).  However, we are unaware of any 318 
studies assessing the use of steroids in PACG (apart from prophylaxis in unaffected but at-risk eyes).  319 
As would be anticipated, PGs recommended a greater number of specific ophthalmic diagnostics.  320 
GP suggestions for additional investigation generally agreed with PG recommendations when the 321 
suggested test was inexpensive and did not require specialized equipment or expertise.  In 322 
particular, gonioscopy may be difficult to master without routine practice and we are not aware of 323 
any readily available training resources for GPs. 324 
 325 
Recheck intervals and judgement regarding natural history and prognosis of KCS and glaucoma were 326 
generally concordant between both groups with one exception:  recheck intervals for KCS were 327 
significantly shorter for GPs than for PGs.  Topical CSA typically lags 3-4 weeks for maximal increase 328 
in tear production (Olivero and others, 1991, Samson and others, 1995).  The shorter median 329 
interval suggested by GPs may reflect severity differences in initial presentation, misunderstanding 330 
  
of CSA pharmacodynamics, decreased clinical confidence, or a variety of other factors not captured 331 
in this survey.  Alternatively, GP versus PG clinic proximity may affect recheck intervals amenable to 332 
clients; however, the similarity of suggested glaucoma recheck intervals between the two groups 333 
argues against client convenience as a driving factor.   334 
  335 
Veterinarians in primary practice are required to have proficiency in multiple domains and may have 336 
limited access to literature unless affiliated with academic practice; availability of veterinary 337 
ophthalmologist advice may also vary due to geographic, social network, and practice 338 
characteristics.  Although management guides used by GPs uniformly recommend CSA and provide 339 
algorithms for the treatment of KCS, most PACG references are less directive in treatment 340 
recommendations and typically provide a more general pharmacologic review, with referral often 341 
recommended as the preferred treatment strategy (Clode, 2015; Colitz, 2010; Reinstein and others, 342 
2009).  We speculate that the wider range of recommendations for PACG encountered amongst our 343 
GP respondents may reflect a lack of clear and concise treatment guidelines for this condition; 344 
guidance which may be particularly needed for cases which cannot be referred.  PGs in this survey 345 
also varied in their treatment recommendations, particularly with respect to the use of 346 
combinations of topical agents; variable use of steroids and antibiotics in the case of KCS, as well as 347 
agents combined with PGAs in PACG, suggest treatment uncertainties which may need additional 348 
data to resolve.  We suggest that establishing current practice in treating companion animal ocular 349 
disease may at least allow for benchmarking of individual practitioners against their colleagues.  350 
Additionally, these surveys can both highlight clinical questions of high priority and identify areas 351 
needful of consensus guidance when evidence is lacking.  We suggest incorporation of Delphi or 352 
similar anonymized methods in formulating veterinary ophthalmology guidelines (Jones and Hunter, 353 
1995).   Adherence, credibility, and feasibility of consensus guidelines is suggested to improve when 354 
general practitioners are included on consensus panels (Allan et al., 2015; Carlsen, Glenton, and 355 
Pope, 2007; Carlsen and Norheim, 2008; Rashidian, Eccles, and Russell, 2008).  Assemblage of 356 
electronic cohort data from both referral and first opinion practices, as well as consideration of 357 
multi-centre pragmatic clinical trials, may be cost-effective paths to generating better and externally 358 
valid evidence. 359 
 360 
Study limitations 361 
This survey was distributed to a subset of RCVS registered veterinarians who had expressed 362 
willingness to be contacted by the CEVM, as well as to attendees at an ophthalmology meeting.  363 
Additionally, although the majority of respondents completed the survey via a web-based 364 
instrument, questionnaire format (paper versus web-based) may have resulted in qualitative or 365 
quantitative differences in responses.  Several levels of self-selection bias may have been 366 
introduced: veterinarians who were willing to be contacted may have a greater interest in evidence-367 
based medicine while veterinarians who responded to the web-based survey may have better access 368 
or understanding of a web-based instruments.  Respondents were more likely to be female and 369 
newer graduates than RCVS members in total; a contemporary survey of RCVS members found a 370 
median qualification year of 1991, with approximate gender parity in registered members 371 
(Robertson-Smith and others, 2010).  As with any vignette-based survey, conformity of 372 
recommendations to actual practice cannot be established. 373 
 374 
Conclusion 375 
  
This survey of veterinarians in the United Kingdom found variation in the treatment of KCS and PACG 376 
between practitioners.  Variation in management may be driven by a limited evidence base, lack of 377 
clinical guidelines, heterogeneous training and practice settings, and clinical confidence or interest 378 
on the part of respondents.  Additionally, greater treatment variation was found in management of 379 
PACG, a condition for which no approved veterinary products are available. Further work is needed 380 
in assessing factors responsible for treatment variation and in optimizing resources and strategies 381 
for building and disseminating evidence-graded, relevant diagnostic and treatment 382 
recommendations to practitioners.   383 
 384 
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Figure 1  538 
Eight most common recommended topical treatment combinations for KCS (numbers indicate 539 
number of respondents nominating that combination, percentage of total respondents 540 
recommending KCS treatments was 330 GPs, 70 PGs) 541 
 542 
543 
  
Figure 2  544 
Additional diagnostic tests recommended by those who suggested further evaluation for KCS 545 
(numbers indicate number of respondents nominating that diagnostic test, percentage of total 546 
respondents recommending KCS diagnostics was 197 GPs, 55 PGs) 547 
548 
  
Figure 3 549 
Most common recommended topical treatment combinations for glaucoma (CAI = topical carbonic 550 
anhydrase inhibitor; PGA = prostaglandin analog, (numbers indicate number of respondents 551 
recommending that glaucoma treatment, percentage of total respondents recommending KCS 552 
diagnostics was 260 GPs, 70 PGs) 553 
 554 
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Figure 4  557 
Additional diagnostic tests recommended by those who suggested further evaluation for glaucoma 558 
(numbers indicate number of respondents nominating that diagnostic test, percentage of total 559 
respondents recommending glaucoma diagnostics was 191 GPs, 69 PGs) 560 
 561 
 562 
